Dr Kurzrock has served as the Principal Investigator (PI) on more than 90 clinical trials, and has overseen approximately 300 clinical trials, mainly using novel targeted molecules, several of which have gone on to FDA approval. She has been the Principal Investigator of the National Cancer Institute U01 Phase I Studies of Targeted Anti-Cancer Agents. She has also been the PI and co-PI of multiple other awards including the University of Texas Clinical and Translational Science Award (co-PI; 35 million dollars).
Dr Kurzrock also created and directed two innovative education programs: the MS/PhD program in Patient-Based Biological Research (U. of Texas Graduate School of Biomedical Sciences) as well as the Phase I Clinical Trials Fellowship. She has been awarded numerous grants and contracts totaling more than $10 million in FY12 alone, and has published nearly 500 peer-reviewed articles in a variety of elite medical journals. In addition, she is Chair of the Southwest Oncology Group (SWOG) Early Therapeutics Committee and on their Board of Governors. More recently, she also joined the Board of Directors for the National Comprehensive Cancer Network (NCCN).